CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced the completion of the public offering of 5,500,000 shares of its common stock. The net proceeds to Dyax from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $20.5 million. Dyax intends to use the net proceeds from the offering to fund the development and commercialization of DX-88, the Company’s ongoing research and preclinical activities, and for general corporate purposes.
